FDA’s Decentralized Trial Guidance: Investigator, Health Care Provider Demarcation Raises Questions
Executive Summary
The investigator's ability to delegate trial-related activities to local HCPs could create operational and reimbursement challenges, as well as potentially boost patient recruitment, stakeholders said. The guidance does not address digital divide and how to deal with a massive influx of data.